This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goldenberg, D. M. Articles by Beach, J. L. Search for Related Content PubMed PubMed Citation Articles by Goldenberg, D. M. Articles by Beach, J. L.

Experimental Radioimmunotherapy of a Xenografted Human Colonic Tumor (GW-39) Producing Carcinoembryonic Antigen¹

Division of Experimental Pathology, Department of Pathology [D. M. G., S. A. G., S. J. B.] and Department of Radiation Medicine [J. L. B.], University of Kentucky College of Medicine, Lexington, Kentucky 40536

Experiments were undertaken to evaluate the antitumor effects of ¹³¹I-labeled goat antibody immunoglobulin G prepared against carcinoembryonic antigen in hamsters bearing the carcinoembryonic antigen-producing GW-39 human colonic carcinoma. At a single injection of 1 mCi ¹³¹I and higher, a marked growth inhibition of GW-39 tumors, as well as a considerable increase in the survival time of the tumor-bearing hamsters, could be achieved. At a dose of 1 mCi, the radioactive affinity-purified antibody appeared to be superior to radioactive normal goat immunoglobulin G in influencing tumor growth and survival time, but no signficant difference could be seen at the higher dose of 2 mCi given. Radiobiological calculations indicated that the tumors received, at up to 20 days after therapy, 1325 rads for the specific antibody and only 411 rads for the normal immunoglobulin G preparation. These findings encourage the further evaluation of antibodies to tumor markers for isotopic cancer therapy.

¹ Supported in part by NIH Grant CA 17742.

² To whom requests for reprints should be addressed, at the Division of Experimental Pathology, MS-409, University of Kentucky College of Medicine, Lexington, Kentucky 40536.

Received 5/15/81. Accepted 7/31/81.